Ki-67 labeling: A more sensitive indicator of malignant phenotype than mitotic count or tumor size?

被引:37
作者
Lowe, Kevin [1 ]
Khithani, Amit [2 ]
Liu, Elizabeth [2 ]
Winston, Tanyss [2 ]
Christian, Derrick [1 ]
Saad, Joe [3 ]
Jeyarajah, Dhiresh Rohan [1 ]
机构
[1] Methodist Dallas Med Ctr, Dept HPB Surg, Dallas, TX 75208 USA
[2] Methodist Dallas Med Ctr, Ctr Canc, Dallas, TX 75208 USA
[3] Methodist Dallas Med Ctr, Dept Pathol, Dallas, TX 75208 USA
关键词
pancreatic neuroendocrine tumors; malignant phenotype; lymph node metastases; NEUROENDOCRINE TUMORS; SURVIVAL; SYSTEM;
D O I
10.1002/jso.23124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives The Ki-67 index has been incorporated into The World Health Organization's classification system of pancreatic neuroendocrine tumors. However, pathologists continue to question the utility of Ki-67 index over that of mitotic count as an indicator of proliferative activity. The intent of the current study is to compare K-i67 index with tumor size and mitotic rate for the association of each with lymph node metastasis and survival. Methods The current study is a review of 24 patients with pancreatic neuroendocrine tumors. Results Regional LNM were present in 100% of tumors with Ki-67 index >10%, while only 25% of tumors with <10% Ki-67 had LNM (P?=?0.003). No tumors <2?cm had >10% Ki-67 labeling. Of patients with tumors showing =10% Ki-67 labeling, 80% died during the observation period of this study, while during the same time period, no patients with <10% Ki-67 labeling died. Conclusion Ki-67 index of >10% is a sensitive indicator of malignant behavior and mortality. Future advances in management of pNETs will require development of staging guidelines with higher predictive value. Inclusion of Ki-67 labeling >10% as an indicator of aggressive disease may contribute to such improvements. J. Surg. Oncol. 2012; 106:724727. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:724 / 727
页数:4
相关论文
共 17 条
[1]   Ki67 protein: the immaculate deception? [J].
Brown, DC ;
Gatter, KC .
HISTOPATHOLOGY, 2002, 40 (01) :2-11
[2]   Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution [J].
Ekeblad, Sara ;
Skogseid, Britt ;
Dunder, Kristina ;
Oberg, Kjell ;
Eriksson, Barbro .
CLINICAL CANCER RESEARCH, 2008, 14 (23) :7798-7803
[3]  
Hemminki K, 2001, CANCER, V92, P2204, DOI 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO
[4]  
2-R
[5]  
IARC, 2004, HLTH ORG CLASS PATH
[6]   Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set [J].
Klimstra, David S. ;
Modlin, Irvin R. ;
Adsay, N. Volkan ;
Chetty, Runjan ;
Deshpande, Vikram ;
Goenen, Mithat ;
Jensen, Robert T. ;
Kidd, Mark ;
Kulke, Matthew H. ;
Lloyd, Ricardo V. ;
Moran, Cesar ;
Moss, Steven F. ;
Oberg, Kjell ;
O'Toole, Dermot ;
Rindi, Guido ;
Robert, Marie E. ;
Suster, Saul ;
Tang, Laura H. ;
Tzen, Chin-Yuan ;
Washington, Mary Kay ;
Wiedenmann, Betram ;
Yao, James .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (03) :300-313
[7]   The gastroenteropancreatic neuroendocrine cell system and its tumors [J].
Klöppel, G ;
Perren, A ;
Heitz, PU .
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 :13-27
[8]   Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors [J].
Modlin, Irvin M. ;
Moss, Steven F. ;
Chung, Daniel C. ;
Jensen, Robert T. ;
Snyderwine, Elizabeth .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18) :1282-1289
[9]  
Oberndorfer S., 1907, FRANKFURT Z PATHOL, V1, P426
[10]   Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center [J].
Pape, UF ;
Böhmig, M ;
Berndt, U ;
Tiling, N ;
Wiedenmann, B ;
Plöckinger, U .
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 :222-233